Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
5822034 | Antiviral Research | 2015 | 5 Pages |
Abstract
The neuraminidase (NA) inhibitors oseltamivir and zanamivir are administered twice daily for 5Â days for treatment of influenza. Laninamivir is a 7-methoxy derivative of zanamivir, but a single dose is effective when taken as the laninamivir octanoate prodrug. We show here in IC50 kinetics assays and a solid phase reactivation assay that compared to zanamivir laninamivir also demonstrates slow binding to but slower dissociation from multiple wild type NAs. A D197E mutation in an influenza B and an E119G in an N9 neuraminidase which confer 15- and 150-fold resistance to laninamivir result in faster binding and dissociation. Despite similar IC50s our assays demonstrate more rapid dissociation of laninamivir from clade 1 compared to 2 H5N1 NAs.
Keywords
Related Topics
Life Sciences
Immunology and Microbiology
Virology
Authors
Jennifer L. McKimm-Breschkin, Susan Barrett,